Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.21
GNMK's Cash-to-Debt is ranked lower than
59% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. GNMK: 1.21 )
Ranked among companies with meaningful Cash-to-Debt only.
GNMK' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.21  Med: 89.71 Max: No Debt
Current: 1.21
Equity-to-Asset 0.42
GNMK's Equity-to-Asset is ranked lower than
79% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. GNMK: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
GNMK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.82 Max: 0.92
Current: 0.42
0.42
0.92
Piotroski F-Score: 2
Altman Z-Score: 0.29
Beneish M-Score: -2.69
WACC vs ROIC
6.49%
-381.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -98.20
GNMK's Operating Margin % is ranked lower than
78% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. GNMK: -98.20 )
Ranked among companies with meaningful Operating Margin % only.
GNMK' s Operating Margin % Range Over the Past 10 Years
Min: -4488.56  Med: -127.65 Max: -98.2
Current: -98.2
-4488.56
-98.2
Net Margin % -101.61
GNMK's Net Margin % is ranked lower than
77% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. GNMK: -101.61 )
Ranked among companies with meaningful Net Margin % only.
GNMK' s Net Margin % Range Over the Past 10 Years
Min: -4383.77  Med: -125.07 Max: -101.61
Current: -101.61
-4383.77
-101.61
ROE % -143.22
GNMK's ROE % is ranked lower than
93% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. GNMK: -143.22 )
Ranked among companies with meaningful ROE % only.
GNMK' s ROE % Range Over the Past 10 Years
Min: -285.43  Med: -92.73 Max: -40.63
Current: -143.22
-285.43
-40.63
ROA % -72.79
GNMK's ROA % is ranked lower than
85% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. GNMK: -72.79 )
Ranked among companies with meaningful ROA % only.
GNMK' s ROA % Range Over the Past 10 Years
Min: -186.91  Med: -67.03 Max: -35.46
Current: -72.79
-186.91
-35.46
ROC (Joel Greenblatt) % -299.56
GNMK's ROC (Joel Greenblatt) % is ranked lower than
75% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. GNMK: -299.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNMK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1238.95  Med: -441.27 Max: -299.56
Current: -299.56
-1238.95
-299.56
3-Year Revenue Growth Rate 12.90
GNMK's 3-Year Revenue Growth Rate is ranked higher than
72% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. GNMK: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNMK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.2  Med: 23.85 Max: 52.5
Current: 12.9
-22.2
52.5
3-Year EBITDA Growth Rate 5.10
GNMK's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. GNMK: 5.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNMK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.4  Med: -17.15 Max: 5.1
Current: 5.1
-63.4
5.1
3-Year EPS without NRI Growth Rate 6.60
GNMK's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. GNMK: 6.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNMK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: -17.05 Max: 6.6
Current: 6.6
-62.8
6.6
GuruFocus has detected 7 Warning Signs with GenMark Diagnostics Inc $GNMK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNMK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:CRY, NAS:AXGN, NAS:TCMD, NAS:EXAC, NYSE:IVC, NAS:XENT, OTCPK:SBMAF, NAS:ELOS, NAS:ARAY, NAS:VRAY, AMEX:CVRS, OTCPK:MZRTF, NAS:OFIX, NAS:CUTR, NAS:RTIX, OTCPK:IPDQF, OTCPK:XVIPF, NAS:VASC, NAS:CSII, NAS:OBLN » details
Traded in other countries:GNF.Germany,
Headquarter Location:USA
GenMark Diagnostics Inc is a molecular diagnostics company. The Company develops and commercializes its proprietary eSensor detection technology for the support of instruments and molecular tests.

GenMark Diagnostics Inc was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.

Ratios

vs
industry
vs
history
PB Ratio 21.80
GNMK's PB Ratio is ranked lower than
98% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. GNMK: 21.80 )
Ranked among companies with meaningful PB Ratio only.
GNMK' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 5.04 Max: 23.3
Current: 21.8
1.61
23.3
PS Ratio 11.14
GNMK's PS Ratio is ranked lower than
85% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. GNMK: 11.14 )
Ranked among companies with meaningful PS Ratio only.
GNMK' s PS Ratio Range Over the Past 10 Years
Min: 4.97  Med: 14.12 Max: 24.66
Current: 11.14
4.97
24.66
Current Ratio 2.00
GNMK's Current Ratio is ranked lower than
63% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. GNMK: 2.00 )
Ranked among companies with meaningful Current Ratio only.
GNMK' s Current Ratio Range Over the Past 10 Years
Min: 2  Med: 6.34 Max: 14.02
Current: 2
2
14.02
Quick Ratio 1.57
GNMK's Quick Ratio is ranked lower than
59% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. GNMK: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
GNMK' s Quick Ratio Range Over the Past 10 Years
Min: 1.57  Med: 6.15 Max: 13.78
Current: 1.57
1.57
13.78
Days Inventory 83.93
GNMK's Days Inventory is ranked higher than
73% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. GNMK: 83.93 )
Ranked among companies with meaningful Days Inventory only.
GNMK' s Days Inventory Range Over the Past 10 Years
Min: 47.43  Med: 65.24 Max: 182.73
Current: 83.93
47.43
182.73
Days Sales Outstanding 53.85
GNMK's Days Sales Outstanding is ranked higher than
72% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. GNMK: 53.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNMK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.08  Med: 63.41 Max: 96.52
Current: 53.85
38.08
96.52
Days Payable 95.91
GNMK's Days Payable is ranked higher than
71% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. GNMK: 95.91 )
Ranked among companies with meaningful Days Payable only.
GNMK' s Days Payable Range Over the Past 10 Years
Min: 70.64  Med: 104.28 Max: 266.25
Current: 95.91
70.64
266.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
GNMK's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. GNMK: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -172.9  Med: -39.65 Max: -3.9
Current: -3.9
-172.9
-3.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 114.00
GNMK's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. GNMK: 114.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNMK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.82  Med: 6.07 Max: 116.55
Current: 114
1.82
116.55
Price-to-Tangible-Book 24.12
GNMK's Price-to-Tangible-Book is ranked lower than
93% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. GNMK: 24.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNMK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64  Med: 5.29 Max: 24.61
Current: 24.12
1.64
24.61
Price-to-Median-PS-Value 0.79
GNMK's Price-to-Median-PS-Value is ranked higher than
71% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. GNMK: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNMK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 0.94 Max: 1.64
Current: 0.79
0.39
1.64
Earnings Yield (Greenblatt) % -8.48
GNMK's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. GNMK: -8.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNMK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -358.7  Med: -12.1 Max: -4.7
Current: -8.48
-358.7
-4.7

More Statistics

Revenue (TTM) (Mil) $50.75
EPS (TTM) $ -1.14
Beta0.70
Short Percentage of Float16.85%
52-Week Range $7.82 - 13.67
Shares Outstanding (Mil)47.09

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 66 95
EPS ($) -1.00 -0.61
EPS without NRI ($) -1.00 -0.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye Nov 09 2015 
Weekly CFO Buys Highlight: SunEdison Inc, Genpact Ltd, GenMark Diagnostics Inc. Aug 31 2015 
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
GenMark Diagnostics Prices Upsized Public Offering of Common Stock Jun 13 2017
GenMark Diagnostics Commences Public Offering of Common Stock Jun 12 2017
GenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : June 12, 2017 Jun 12 2017
GenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen... Jun 12 2017
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : June 9,... Jun 09 2017
GenMark Diagnostics to Present at the 2017 William Blair Growth Stock Conference May 31 2017
ETFs with exposure to GenMark Diagnostics, Inc. : May 5, 2017 May 05 2017
Edited Transcript of GNMK earnings conference call or presentation 2-May-17 8:30pm GMT May 05 2017
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 5,... May 05 2017
GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference May 03 2017
GenMark Diagnostics reports 1Q loss May 02 2017
Investor Network: GenMark Diagnostics, Inc. to Host Earnings Call May 02 2017
CORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification... Apr 20 2017
GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 Apr 18 2017
ETFs with exposure to GenMark Diagnostics, Inc. : April 13, 2017 Apr 13 2017
GenMark Diagnostics to Present at 16th Annual Needham Healthcare Conference Mar 28 2017
GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
GenMark Diagnostics to Present at Cowen and Company’s 37th Annual Health Care Conference Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}